polatuzumab vedotin
Selected indexed studies
- Polatuzumab Vedotin in Previously Untreated Diffuse Large B-Cell Lymphoma. (N Engl J Med, 2022) [PMID:34904799]
- Polatuzumab Vedotin. (, 2006) [PMID:37247366]
- Polatuzumab Vedotin in Relapsed or Refractory Diffuse Large B-Cell Lymphoma. (J Clin Oncol, 2020) [PMID:31693429]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- Polatuzumab Vedotin in Previously Untreated Diffuse Large B-Cell Lymphoma. (2022) pubmed
- Polatuzumab Vedotin. (2006) pubmed
- Polatuzumab Vedotin in Relapsed or Refractory Diffuse Large B-Cell Lymphoma. (2020) pubmed
- Polatuzumab Vedotin. (2012) pubmed
- Polatuzumab Vedotin: First Global Approval. (2019) pubmed
- Mosunetuzumab Plus Polatuzumab Vedotin in Transplant-Ineligible Refractory/Relapsed Large B-Cell Lymphoma: Primary Results of the Phase III SUNMO Trial. (2025) pubmed
- Glofitamab with Polatuzumab Vedotin in Refractory Burkitt's Lymphoma. (2025) pubmed
- Mosunetuzumab with polatuzumab vedotin in relapsed or refractory aggressive large B cell lymphoma: a phase 1b/2 trial. (2024) pubmed
- Polatuzumab Vedotin: a New Target for B Cell Malignancies. (2020) pubmed
- Spotlight on polatuzumab vedotin: new standards for diffuse large B-cell lymphoma? (2024) pubmed